Renoprotective effect of Tanshinone IIA, an active component of Salvia miltiorrhiza, on rats with chronic kidney disease

Phytotherapy Research

Volumn 24, Issue 12, 2010, Pages 1886-1892

  Ahn, Young Min ^a   Kim, Su Kang ^a   Lee, Sang Hun ^a   Ahn, Se Young ^a   Kang, Sung Wook ^a   Chung, Joo Ho ^a   Kim, Sung Do ^a   Lee, Byung Cheol ^a  

^a Kyung Hee University   (South Korea)

Author keywords

chronic kidney disease; nephrectomy; renoprotection; Tanshinone IIA

Indexed keywords

ALBUMIN; ANGIOTENSIN II; CHOLESTEROL; COLLAGEN TYPE 4; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TANSHINONE IIA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SALVIA MILTIORRHIZA; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; COLLAGEN TYPE IV; CREATININE; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; KIDNEY; MALE; PHENANTHRENES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; SALVIA MILTIORRHIZA; TRANSFORMING GROWTH FACTOR BETA1;

RATTUS; SALVIA MILTIORRHIZA;

EID: 78649652536     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3347     Document Type: Article

References (34)

1. Anderson PW, Do YS, Hsueh WA,. 1993. Angiotensin II causes mesangial cell hypertrophy. Hypertension 21: 29-35.
2. Eknoyan G, Lameire N, Barsoum R, et al. 2004. The burden of kidney disease: improving global outcomes. Kidney Int 66: 1310-1314.
3. el-Agroudy AE, Hassan NA, Foda MA, et al. 2003. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 23: 300-306.
4. Fogo AB., 1999. Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 7: 147-159.
5. Gilbertson DT, Liu J, Xue JL, et al. 2005. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16: 3736-3741.
6. Jang SI, Jeong SI, Kim KJ, et al. 2003. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Med 69: 1057-1059.
7. Ji Z, Huang C, Liang C, et al. 2005. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis. Cell Mol Immunol 2: 150-154.
8. Johnson RJ, Alpers CE, Yoshimura A, et al. 1992. Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474.
9. Kim H, Lee E, Lee S, et al. 1998. Effect of Rehmannia glutinosa on immediate type allergic reaction. Int J Immunopharmacol 20: 231-240.
10. Kim DD, Sánchez FA, Durán RG, et al. 2007. Endothelial nitric oxide synthase is a molecular vascular target for the Chinese herb Danshen in hypertension. Am J Physiol Heart Circ Physiol 292: H2131-H2137.
11. Kim SK, Jung KH, Lee BC,. 2009. Protective effect of Tanshinone IIA on the early stage of experimental diabetic nephropathy. Biol Pharm Bull 32: 220-224.
12. Kurogi Y,. 2003. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 23: 15-31.
13. Lee AR, Wu WL, Chang WL, et al. 1987. Isolation and bioactivity of new tanshinones. J Nat Prod 50: 157-160.
14. Lee LK, Meyer TW, Pollock AS, et al. 1995. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96: 953-964.
15. Lewis EJ, Hunsicker LG, Bain RP, et al. 1993. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462.
16. Lu XY, Li M, Weng MW,. 2007. Inhibition effects of constituents of Radix Salviae Miltiorrhizae on proliferation and procollagen transcription of dermal fibroblasts in systemic sclerosis. Zhonghua Yi Xue Za Zhi 87: 2426-2428.
17. Maki DD, Ma JZ, Louis TA, et al. 1995. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155: 1073-1080.
18. Nakamura T, Obata J, Kimura H, et al. 1999. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 55: 877-889.
19. Niu XL, Ichimori K, Yang X, et al. 2000. Tanshinone II-A inhibits low density lipoprotein oxidation in vitro. Free Radic Res 33: 305-312.
20. Norman JT, Fine LG,. 1999. Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Exp Nephrol 7: 167-177.
21. Ray PE, Bruggeman LA, Horikoshi S, et al. 1994. Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 45: 177-184.
22. Remuzzi G, Bertani T,. 1998. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456.
23. Roberts AB, McCune BK, Sporn MB., 1992. TGF-beta: regulation of extracellular matrix. Kidney Int 41: 557-559.
24. Ruggenenti P, Schieppati A, Remuzzi G,. 2001. Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608.
25. Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al. 2001. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329.
26. Ryu SY, No Z, Kim SH, et al. 1997. Two novel abietane diterpenes from Salvia miltiorrhiza. Planta Med 63: 44-46.
27. Song Y, Li C, Cai L,. 2004. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 76: 66-75.
28. Steffes MW, Osterby R, Chavers B, et al. 1989. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077-1081.
29. Tang J, Zhan C, Zhou J,. 2008. Effects of tanshinone IIA on transforming growth factor beta1-Smads signal pathway in renal interstitial fibroblasts of rats. J Huazhong Univ Sci Technolog Med Sci 28: 539-542.
30. Thilo W., 1975. [Principles for the state control of oral vaccines against bacterial intestinal infections]. Z Gesamte Hyg 21: 888-891.
31. Wang AM, Sha SH, Lesniak W, et al. 2003. Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother 47: 1836-1841.
32. Winer N, Sowers JR,. 2004. Epidemiology of diabetes. J Clin Pharmacol 44: 397-405.
33. Wolf G, Haberstroh U, Neilson EG,. 1992. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140: 95-107.
34. Wolf G, Neilson EG,. 1993. Angiotensin II as a renal growth factor. J Am Soc Nephrol 3: 1531-1540.